SAN FRANCISCO, CA—Use of a novel “unlocking” coronary device is associated with nearly a 50% reduction in the risk of target lesion failure between 6 months and 2 years, according to a landmark ...
LONDON, England—A device designed to deter accruing risks of stent-related adverse events has proven itself once again in a noninferiority trial against a workhorse drug-eluting stent, results from ...
MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, ...
For percutaneous coronary intervention (PCI) on de novo lesions, the DynamX bioadaptor not only matched drug-eluting stents (DES) in early performance but seemed to keep stent-related events from ...
Elixir Medical Corp. reported positive 12-month data from the Infinity-Swedeheart trial that compared its Dynamx coronary bioadaptor system to Medtronic plc’s Resolute Onyx zotarolimus drug-eluting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results